TipRanks
Go Ultimate55% OFF

Neurocrine (NBIX) Revenue by Segment

Revenue by Segment

Shows how revenue is distributed across different business areas, highlighting which segments are driving growth and which may need strategic focus or improvement.

$0.00$200.00M$400.00M$600.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

INGREZZA remains the dominant growth driver, overcoming historical Q1 payer seasonality to reach a new, higher revenue baseline; smaller legacy and collaboration lines contribute only marginally. Management’s commentary is the key change: an early but fast Cranesity ramp (management says it’s already annualizing at a material run‑rate) plus the pending Soleno deal could materially diversify revenue and reduce single‑product risk, but investors should monitor gross‑to‑net pressure, recurring Q1 reauthorization effects, and stepped-up R&D/commercial spend as potential near‑term margin headwinds.

NBIX Revenue by Segment

DateIngrezzaOngentys and Other ProductsCollaboration and Other
Jun 30, 2026$716.00M$0.00$4.70M
Mar 31, 2026$656.90M$0.00$4.30M
Dec 31, 2025$657.50M$5.50M$7.20M
Sep 30, 2025$686.60M$5.20M$5.00M
Jun 30, 2025$624.40M$4.40M$5.50M
Mar 31, 2025$545.20M$4.00M$8.90M
Dec 31, 2024$615.00M$6.20M$6.50M
Sep 30, 2024$612.90M$3.70M$5.50M
Jun 30, 2024$579.50M$4.30M$6.40M
Mar 31, 2024$506.00M$3.00M$6.30M
Dec 31, 2023$500.20M$7.00M$8.00M
Sep 30, 2023$485.70M$6.10M$7.00M
Jun 30, 2023$439.70M$6.60M$6.40M
Mar 31, 2023$410.40M$4.90M$5.10M
Dec 31, 2022$399.20M$5.40M$7.40M
Sep 30, 2022$376.40M$2.90M$8.60M
Jun 30, 2022$349.60M$2.40M$26.20M
Mar 31, 2022$302.60M$2.40M$5.60M
Dec 31, 2021$301.00M$2.50M$8.50M
Sep 30, 2021$286.50M$2.30M$7.20M
Jun 30, 2021$264.80M$2.00M$22.10M
Mar 31, 2021$229.60M$1.40M$5.60M
Dec 31, 2020$240.40M$900.00K$6.60M
Sep 30, 2020$254.00M$100.00K$4.40M
Jun 30, 2020$267.60M$0.00$34.80M
Mar 31, 2020$0.00$0.00$6.00M
Dec 31, 2019$0.00$0.00$6.20M